Form 4 for AXGN Axogen, Inc.
Accepted 2025-12-10 00:00:00 ET · period of report 2025-12-08 · accession 0001410781-25-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-10 | 2025-12-08+ | AXGN | JOHNSON JOHN | Dir | S - Sale+OE | $30.64 | -45.4K | 13.1K | -78% | -$1.39M |
| DM | 2025-12-10 | 2025-12-08+ | AXGN | JOHNSON JOHN | Dir | M - OptEx | $6.30 | +20.4K | 25.0K | +445% | +$128.7K |
| DM | 2025-12-10 | 2025-12-08+ | AXGN | JOHNSON JOHN | Dir | M - OptEx | $0.00 | -20.4K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-09 | S | D | 8,545 | $29.98 | 13,141 | D | — | — | (F2) The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.98 to $30.02 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2025-12-09 | M | A | 8,545 | $6.30 | 21,686 | D | — | — | |
| 3 | Common | Common Stock | 2025-12-08 | S | D | 11,891 | $31.22 | 13,141 | D | — | — | (F1) The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2025-12-08 | M | A | 11,891 | $6.30 | 25,032 | D | — | — | |
| 5 | Common | Common Stock | 2025-12-09 | S | D | 13,141 | $29.98 | 0 | D | — | — | (F3) The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.90 to $30.09 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| 6 | Common | Common Stock | 2025-12-08 | S | D | 11,802 | $31.26 | 13,141 | D | — | — | (F1) The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| 7 | Derivative | Stock Option (right to purchase) | 2025-12-08 | M | D | 11,891 | $0.00 | 8,545 | D | $6.30 · — to 2033-09-01 | 11,891 Common Stock | (F4) Non-qualified stock option portion of the 2023 annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The grant became fully vested on September 1, 2024, the one-year anniversary of the grant date. |
| 8 | Derivative | Stock Option (right to purchase) | 2025-12-09 | M | D | 8,545 | $0.00 | 0 | D | $6.30 · — to 2033-09-01 | 8,545 Common Stock | (F4) Non-qualified stock option portion of the 2023 annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The grant became fully vested on September 1, 2024, the one-year anniversary of the grant date. |